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Abstract: Fibrolase is the fibrinolytic enzyme isolated from Agkistrodon contortrix contortrix 
(southern  copperhead  snake)  venom.  The  enzyme  was  purified  by  a  three-step  HPLC 
procedure and was shown to be homogeneous by standard criteria including reverse phase 
HPLC, molecular sieve chromatography and SDS-PAGE. The purified enzyme is a zinc 
metalloproteinase containing one mole of zinc. It is composed of 203 amino acids with a 
blocked amino-terminus due to cyclization of the terminal Gln residue. Fibrolase shares a 
significant  degree  of  homology  with  enzymes  of  the  reprolysin  sub-family  of 
metalloproteinases  including  an  active  site  homology  of  close  to  100%;  it  is  rapidly 
inhibited by chelating agents such as EDTA, and by alpha2-macroglobulin (). The 
enzyme is a direct-acting thrombolytic agent and does not rely on plasminogen for clot 
dissolution. Fibrolase rapidly cleaves the A()-chain of fibrinogen and the B()-chain at a 
slower rate; it has no activity on the -chain. The enzyme exhibits the same specificity with 
fibrin, cleaving the -chain more rapidly than the -chain. Fibrolase was shown to have 
very effective thrombolytic activity in a reoccluding carotid arterial thrombosis model in 
the  canine.  A  recombinant  version  of  the  enzyme  was  made  in  yeast  by  Amgen,  Inc. 
(Thousand Oaks, CA, USA) and called alfimeprase. Alfimeprase is identical to fibrolase 
except for a two amino acid truncation at the amino-terminus and the insertion of a new 
amino-terminal amino acid in the truncated protein; these changes lead to a more stable 
enzyme for prolonged storage. Alfimeprase was taken into clinical trials by Nuvelo, Inc. 
(San Carlos, CA), which licensed the enzyme from Amgen. Alfimeprase was successful in 
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Phase I and II clinical trials for peripheral arterial occlusion (PAO) and central venous 
access device (CVAD) occlusion. However, in Phase III trials alfimeprase did not meet the 
expected end points in either PAO or CVAD occlusion and in a Phaase II stroke trial, and 
Nuvelo dropped further development in 2008. 
Keywords:  fibrolase;  alfimeprase;  thrombolysis;  peripheral  arterial  occlusion;  animal 
models;  central  venous  access  device  occlusion;  stroke;  alpha2  macroglobulin; 
metalloproteinase 
 
1. Introduction and Background 
Kornalik  in  Czechoslovakia  in  1966  was  the  first  to  report  fibrinolytic  activity  in  Agkistrodon 
contortrix contortrix (southern copperhead snake) venom [1], although earlier Didisheim and Lewis 
had suggested that snake venoms may contain fibrinolytic activity that should be useful for clinical 
application since it may not be inactivated by inhibitors in mammalian blood [2]. However, it was not 
until much later that the fibrinolytic enzyme was purified. The Markland laboratory, at the University 
of Southern California (USC), first identified the enzyme in 1982 [3] and subsequently purified it [4]. 
Fibrolase was the name given to this fibrinolytic metalloproteinase.  
Fibrolase is a direct acting, 23-kDa fibrinolytic enzyme that cleaves the A-chain of fibrinogen 
(primary cleavage site Lys-Leu bond at residues 413–414). The enzyme also cleaves the B-chain at a 
slower rate, but it has no effect on the -chain [5]. The enzyme was purified by 3-step HPLC method 
involving hydrophobic interaction HPLC, hydroxyapatite HPLC and cation exchange HPLC  [4,6]. 
Fibrolase  is  a  member  of  family  M12,  subfamily  B  (the  reprolysins),  a  grouping  of  proteolytic 
enzymes composed of many enzymes of snake venom origin. The active site of the molecule has been 
identified in the zinc-binding region of fibrolase, spanning amino acids 141–170 [7,8]. 
Fibrolase differs from the plasminogen activator-based thrombolytics since it acts directly on fibrin; 
it does not rely on activation of plasminogen (fibrolase neither activates nor degrades plasminogen) 
[5]. Fibrolase is a metalloproteinase and not a serine protease [5]. Therefore, it is not inhibited by the 
blood serine protease inhibitors, SERPINS [9], which are targeted to the blood clotting and fibrinolytic 
serine proteinases. However, incubation of fibrolase with plasma leads to inhibition of fibrinolytic 
activity due to the covalent binding of fibrolase by alpha-2 macroglobulin (2M) [10,11]. The amino 
acid sequence of fibrolase was determined in a collaboration between the Markland laboratory and 
investigators at Chiron Corp. (Emeryville, CA, USA) [7], and the sequence clearly shows that the 
enzyme is a member of the M12 group of metalloproteinases, the reprolysins. Further, the sequence 
reveals that there is a complete absence of consensus sites for N-linked glycosylation (Asn-X-Ser/Thr). 
Separate  studies  indicated  that  the  enzyme  has  no  thrombin-like  activity,  no  protein  C  activation 
activity, no activation nor degradation of plasminogen, no platelet aggregating activity in vitro, no 
hemolytic activity, and importantly no hemorrhagic activity [12]. 
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2. Evolution of Fibrolase as a Thrombolytic Agent 
Based on the direct action of fibrolase on fibrin and the lack of inhibition by blood SERPINS, it 
appeared  that  fibrolase  should  be  an  effective  thrombolytic  agent.  With  this  as  a  background,  
Dr. Markland and Dr. Benedict Lucchesi, a well-known authority on the use of animal models for 
evaluation of thrombolytic and anti-platelet agents at the University of Michigan, agreed to collaborate 
on a study to assess the potential thrombolytic activity of fibrolase in a canine reoccluding carotid 
arterial  thrombosis  model.  Dr.  Markland  took  fibrolase  to  the  University  of  Michigan  and  with  
Dr. Lucchesi demonstrated that the enzyme isolated from snake venom had excellent lytic activity in 
this 100% reoccluding arterial thrombosis model [13]. The collaborative study showed that the enzyme 
rapidly lysed clots in the carotid artery when administered at a dose of 4 mg/kg in a volume of 3 mL 
infused over a 5 minute period proximal to the site of the thrombus. In this model system, arteries 
infused with fibrolase in five of five dogs were shown to be cleared of the occluding thrombus within  
6 minutes of initiation of lytic agent infusion. In the contralateral carotid artery that received only 
vehicle,  the  vessels  remained  occluded  throughout  the  course  of  the  experiment.  By  comparison, 
animals  receiving  anisoylated  plasminogen  streptokinase  activator  complex  (APSAC)  lysed  the 
thrombus within 26 minutes of infusion. Five minutes after completing fibrolase administration and in 
one group of the two groups administered APSAC, a fibrinogen receptor antagonist, 7E3 (0.8 mg/kg) 
was  administered  intravenously  to  inhibit  platelet  aggregation  and  prevent  reocclusion  of  the 
thrombolytic-treated arteries. After administration of 7E3, four of five carotid arteries in the dogs 
treated with fibrolase remained open for the remainder of the experiment, and six of the six arteries 
treated with APSAC. The average time to thrombus resolution for APSAC was 26 minutes while for 
recombinant fibrolase it was 6 minutes. It was concluded from these studies that fibrolase is an active 
lytic agent and rapidly lyses carotid arterial thrombi without evidence of hemorrhage or compromise of 
the hemodynamic system. In summary, we concluded that in combination with antiplatelet therapy, 
fibrolase  offers  a  unique  mechanism  for  clot  dissolution  that  may  provide  an  alternative  to 
plasminogen activator-based thrombolysis and could have significant potential for clinical application. 
A sideline to this study was a problem that was experienced with the recombinant version of the 
enzyme produced by Chiron under a subcontract from Marion Laboratories, Kansas City, MO (later 
known as Marion Merrell Dow). To exploit the commercial potential of fibrolase, Marion Laboratories 
supported research by the Markland lab and subcontracted Chiron to produce a recombinant version of 
fibrolase.  After  trying  several  different  expression  methods,  Chiron  settled  on  a  yeast  expression 
system and provided the recombinant version of the protein to Dr. Lucchesi. Unfortunately, the two 
dogs  that  were  treated  with  the  recombinant  enzyme  died  shortly  after  treatment,  leading  to  the 
suspicion that the recombinant protein contained an impurity. Based on these findings Dr. Markland 
contacted Dr. Pablo Valenzuela at Chiron, who was Vice President of Research at that time, and 
obtained more of the recombinant protein that was passed through a detox column to remove any 
potential endotoxin contamination. Dr. Markland then took the purified recombinant enzyme back to 
the University of Michigan to examine its activity. This time the enzyme worked, suggesting that the 
original  batch  of  recombinant  fibrolase  had  been  contaminated.  The  results  of  this  study  were 
published jointly with Dr. Lucchesi’s laboratory in 1994 [13]. But, the damage had already been done. 
On the basis of the failed test in the two dogs and other Company related issues, Marion Laboratories Toxins 2010, 2                                    
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decided to pull out of the project. Funding for the project was halted and the research project lay 
fallow for several years. However, Dr. Chris Toombs, Research Scientist at Amgen, read the paper 
describing the thrombolytic activity of recombinant fibrolase [13] and contacted Dr. Markland about 
possible interest by Amgen in the clinical potential of the enzyme. A Material Transfer Agreement and 
a Research Agreement between Amgen and the University of Southern California (USC) was put into 
place to develop the clinical potential of fibrolase; this agreement was in place from 1996 until 2001. 
Table 1 summarizes timelines for the evolution of events involved in the long and winding road to 
clinical trials. 
Table 1. Chronology of fibrolase-alfimeprase evolution to clinical trials. 
1982 
Fibrolase first identified in the Markland laboratory using molecular sieve 
chromatography of Southern copperhead venom 
1986 
US Patent No. 4,610,879 issued to F.S. Markland, Jr. and N.K. Reddy: Fibrinolytic 
Enzyme from snake venom 
1986 
Marion Laboratories, Inc., Kansas City, MO (Marion Merrell Dow, MMD) signs a 
subcontract with Chiron to produce r-fibrolase in yeast or bacteria 
1996–
2001 
Research agreement between USC and Amgen. Amgen produces an altered recombinant 
form of fibrolase in yeast and renames it alfimeprase 
2002 
Nuvelo (then know as Hyseq) obtains rights to alfimeprase from Amgen and initiates 
clinical trials (20 years after protein is discovered). US FDA grants orphan drug status to 
alfimeprase for PAO 
2004 
Amgen licenses alfimeprase to Nuvello with future milestone payments due to Amgen 
(November 2004) 
2006 
FDA grants Nuvelo fast track designation for alfimeprase for the treatment of PAO in 
NAPA-3 Phase III trial (January 2006) 
2006 
Bayer Healthcare signs $385M deal for worldwide (non-USA) rights to alfimeprase with 
Nuvelo, $50M upfront based on Phase II PAO results (January 2006) 
2007 
Bayer pulls out of agreement with Nuvello; Nuvello indicates Phase II study in acute 
ischemic stroke will commence at end of year (June 2007) 
2008 
Nuvelo abandons development of alfimeprase after it fails to meet endpoints in Phase III 
PAO and CO trials and low enrollment in the Phase II stroke treatment trial (March 2008) 
3. The Fibrolase—Alfimeprase Connection 
At Amgen Dr. Toombs led a group of scientists that produced a recombinant version of fibrolase 
truncated by two amino acids at the amino-terminus that was ultimately called alfimeprase; an interim 
terminology of NAT (natural acting thrombolytic) was also used. The truncation was necessitated by 
the presence of several isoforms of the enzyme encountered by Amgen, and previously experienced by 
the Markland laboratory with the natural enzyme [14,15]. Using an E. coli expression system, Amgen 
observed the isoforms during isolation of fibrolase. Additionally, in the E. coli system a significant 
percentage of fibrolase was retained in inclusion bodies resulting in a very low yield of active enzyme. 
In view of these difficulties, a eukaryotic host (a yeast system) was examined for its ability to produce 
active alfimeprase. The yeast Pichia pastoris was chosen as it has been widely used and served as an 
effective host for heterologous expression of recombinant proteins [8]. In the P. pastoris expression 
system, the synthetic gene for alfimeprase is incorporated into the genomic DNA of an untransformed Toxins 2010, 2                                    
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yeast strain. A plasmid is used, which encodes alfimeprase DNA and the enzyme is expressed under 
the control of the alcohol oxidase 1 promoter, which is induced by the presence of methanol and is 
tightly regulated. Methanol not only serves as the sole carbon source for this strain of yeast but also 
induces expression of the target protein. The yeast cells are cultured in an induction medium that 
contains methanol. The secreted alfimeprase is purified from the media and formulated into buffer 
containing Zn
2+ at physiologic pH. 
Alfimeprase contains 201 amino acids with an N-terminal sequence of SFPQR- as compared to 
fibrolase, which contains 203 amino acids with an N-terminal sequence that begins with EQRFPQR-, 
otherwise alfimeprase is identical in structure and enzymatic activity to fibrolase. The CAS Registry 
Service has assigned registery number 259074-76-5 with the index name 3-203 fibrolase [3-serine] 
(Agkistrodon  contortrix  contortrix,  recombinant).  X-ray  crystallographic  data  and  modeling  of  the 
structure  of  fibrolase  indicated  that  the  amino-terminus  of  fibrolase  was  free  to  move  about  in  
three-dimensional space presumably causing instability of the protein [16]. A more stable protein was 
produced as a result of the two amino acid truncation and substitution of Ser for Arg at the new  
amino-terminus.  This  led  to  stability  during  long-term  storage  as  well  as  eliminating  the  isoform 
problem, which originated because of sequence variations at the amino-terminus [15].  
Dr. Toombs, at Amgen, noted that during studies on the lytic activity of fibrolase in a guinea pig 
model,  there  was  transient  hypotension  following  intra-arterial  administration  of  the  enzyme. 
However, this could be prevented by treatment with a bradykinin antagonist. To identify the possible 
mechanism  involved  in  fibrolase-mediated  hypotension,  the  catalytic  activity  of  fibrolase  against 
proteins in the bradykinin synthetic pathway were assessed. There are two biochemical routes that lead 
to the synthesis of bradykinin (Figure 1) [17]. Plasma kallikrein directly cleaves high molecular weight 
kininogen  (HMWK)  generating  bradykinin.  However,  tissue  kallikrein  can  cleave  low  molecular 
weight kininogen (LMWK) to form kallidin a decapeptide. The amino-terminal lysine of kallidin is 
then removed by plasma aminopeptidase to form bradykinin. Bradykinin is subsequently cleaved to the 
inactive heptapeptide Arg-Pro-Pro-Gly-Phe-Ser-Pro by kininase II. The Markland lab determined that 
fibrolase  promotes  bradykinin  formation  by  cleavage  of  LMWK  with  the  formation  of  kallidin. 
Kallidin is a relatively poor substrate for fibrolase. Fibrolase also cleaves bradykinin to the inactive 
heptapeptide  Arg-Pro-Pro-Gly-Phe-Ser-Pro.  Thus,  the  transient  nature  of  the  production  and 
subsequent degradation of bradykinin mimics findings observed with blood pressure alterations in 
animals treated with fibrolase. Fibrolase appears to promote bradykinin generation through the LMWK 
pathway (Figure 1), but has no effect on HMWK. Although kallidin is a poor substrate for fibrolase, 
fibrolase can cleave bradykinin effectively. Analysis of the bradykinin cleavage products by mass 
spectrometry  confirmed  that  fibrolase  cleaves  between  residues  Pro7-Phe8  to  form  the  inactive 
heptapeptide (shown above). In summary, fibrolase can generate kallidin from LMW kininogen and after 
bradykinin is generated by aminopeptidase action, fibrolase cleaves and inactivates bradykinin in a manner 
similar to kininase II. This results in the transient hypotension observed following fibrolase treatment. 
4. Alfimeprase in Vitro Studies 
Dr. Toombs led the preclinical studies of alfimeprase at Amgen. He initiated in vivo studies to 
characterize thrombolytic activity of the enzyme in a number of different animal models and he carried Toxins 2010, 2                                    
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out in vitro studies to characterize the inhibitory activity of 2M on alfimeprase. Dr. Toombs showed 
that  in  the  presence  of  3-fold  molar  excess  2M,  alfimeprase  rapidly  forms  a  complex  with  the 
inhibitor. Using SDS-PAGE and Western blotting with an antibody to alfimeprase, he demonstrated 
that complex formation begins within 5 s and is complete by 1.5 min [18]. The interaction between 
2M and alfimeprase involves covalent bond formation with 1:1 stoichiometry between enzyme and 
inhibitor,  identical  to  the  interaction  of  2M  with  fibrolase.  The  capacity  of  serum  to  bind  and 
neutralize alfimeprase was determined based on the concentration of 2M in human serum (~100 to 
300 mg/dL). The binding capacity of alfimeprase for 2M in human serum was determined and was 
initially estimated to be 40–50 μg alfimeprase per mL of human serum [8]. In a study carried out at 
Amgen, the effect of alfimeprase on human plasma fibrinogen was examined. Plasma was collected 
from 20 human donors and fibrinogen quantified in all samples prior to the addition of alfimeprase; 
following addition of alfimeprase fibrinogen levels in the plasma samples were measured at 30, 60, 
and 120 minutes. Plasma fibrinogen was not affected by incubation with alfimeprase at 10 μg/mL 
(alfimeprase was completely inhibited by 2M). However, with alfimeprase at 100 μg/mL incubation 
of plasma resulted in complete degradation of fibrinogen in all plasma samples within 30 minutes. This 
suggested that at 100 μg/mL alfimeprase, the capacity for 2M to bind and inactivate the enzyme had 
been exceeded. These studies point out the importance of not over-titrating 2M by alfimeprase since 
the  presence  of  an  active  enzyme  in  blood  could  potentially  cause  serious  side  effects  during  
clinical trials. 
Figure 1. Effect of fibrolase on the bradykinin metabolism pathway. 
 
Fibrolase is involved in both the production and degradation of the hypotensive peptide bradykinin. 
This results in a transient drop in blood pressure following systemic administration of fibrolase at 
concentrations exceeding that of alpha-2 macroglobulin. LMW, low molecular weight; HMW, high 
molecular weight. Toxins 2010, 2                                    
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5. Alfimeprase Animal Model Studies 
A number of animal model studies were conducted at Amgen: alfimeprase was investigated in a rat 
acute  carotid  artery  thrombosis  model,  two  piglet  acute  carotid  artery  thrombosis  models,  a  dog 
acute/subacute carotid arterial thrombosis model, and a baboon model involving acute thrombosis in 
exteriorized arteriovenous shunts [8]. Alfimeprase was delivered locally in all of these models to avoid 
the  inhibitory  effect  of  2M,  which  would  have  inactivated  the  enzyme  following  intravenous 
administration (see description in Table 2) [8].  
Table 2. Key Findings from Selected Animal/Human Pharmacology Studies 
1,2. 
Species  Model  Design  Key Findings 
Human  In vitro clot lysis 
Preformed human whole 
blood clots in tubes or 
mounted in PTFE graft 
Rate of clot lysis is directly proportional to 
the quantity of alfimeprase added or 
infused into the graft segment. 
Rat  Acute carotid 
thrombosis 
Alfimeprase (2 mg total) vs. 
UK (250 U/min) 
71% incidence (10/14) of clot lysis in  
6.3 minutes in alfimeprase group vs. 87% 
(13/15) in 33.5 minutes in UK group. 
Piglet 
Acute carotid 
thrombosis; 
thrombus aged for 
30 minutes 
Alfimeprase (5 mg total) vs. 
tPA (2 mg/kg) 
100% incidence (11/11) of clot lysis in 4.4 
minutes with alfimeprase vs. 70% 
incidence (7/10) in 17.8 minutes with tPA. 
Average blood loss: alfimeprase = 1.7 mL, 
t-PA = 17.1 mL 
Piglet 
Acute carotid 
thrombosis; 
thrombus aged for 
30 minutes 
Alfimeprase (3 and 6 mg 
total) vs. UK (500 U/min and 
2,000 U/min) 
83% (10/12) and 91% (10/11) incidence of 
clot lysis in 7.1 and 10.0 minutes for the 3 
and 6 mg groups, respectively.; 17% (2/12) 
and 25% (3/12) incidence of clot lysis in 
39.0 and 28.0 minutes in 500 U/min and 
2000 U/min groups, respectively. 
Dog 
Acute/ subacute 
carotid thrombosis 
thrombus aged for 
30 minutes or 24 
hours 
30 minute: Alfimeprase  
(2 mg/kg) vs. UK (4500 U) 
 
24 hour: Alfimeprase (3.8 
mg/kg) vs. UK (13,500 U) 
In 30 minute old clots, alfimeprase resulted 
in 100% incidence (7/7) of clot lysis in  
7.5 minutes vs. UK with 83% incidence 
(5/6) in 38.8 minutes. 
In 24-hour clots, 75% success (6/8) in  
72 min with alfimeprase vs. 67% success in 
120 minutes using UK. 
Baboon 
Acute thrombosis 
of Dacron ® grafts 
in exteriorized 
arteriovenous 
shunts 
Alfimeprase (1 or 10 
mg/mL) vs. UK (5,000 or 
50,000 U/mL) 
Agents are infused into graft 
segment at 1 μL/min until 
flow is restored 
With 1 mg/mL alfimeprase, flow restored 
in average of 15.5 minutes and with  
10 mg/mL, flow restored in 8.7 minutes. 
With 5000 U/mL UK, flow restored in 
average of 28.3 minutes and with  
50,000 U/mL, flow restored in  
11.7 minutes. A decrease (14% to 17%) in 
fibrinogen and an increase (79% to 176%) 
in D-dimer was noted in the animals treated 
with UK, whereas negligible changes in 
these parameters (± 10% of baseline) 
occurred in alfimeprase treated animals. 
1  Abbreviations:  PTFE  =  polytetrafluoroethylene  (Teflon);  UK  =  urokinase;  tPA  =  tissue  plasminogen 
activator; 
2 Taken from [8], with permission from Bentham Science Publishers. 
 Toxins 2010, 2                                    
 
800 
Amgen  investigators  also  examined  a  porcine  model  of  peripheral  arterial  occlusion  (PAO)  in 
which the carotid artery of adult pigs (~20 cm long) is thrombosed by balloon injury plus thrombin 
administration and stasis. The animals are allowed to recover for 4 days to form a stabilized thrombus. 
In this model of peripheral arterial occlusion (PAO) both the size and age of the thrombus are close 
approximations of the size and duration of ischemic symptoms reported in the largest clinical trial of 
thrombolysis in PAO, the Thrombolysis Or Peripheral Arterial
 Surgery (TOPAS) study [19]. In the 
porcine model a multiple side-hole catheter is advanced for drug delivery into the thrombus. With a 
dose of 30 mg alfimeprase there is close to complete thrombus resolution and flow restoration within 
30 minutes. By comparison, UK 250,000 U bolus plus 4,000 U/min infusion did not give comparable 
results despite continuing infusion for up to 4 hours.  
Separately,  a  study  was  carried  out  by  Dr.  Lucchesi  and  colleagues  to  compare  the  effect  of 
alfimeprase and rt-PA on extent of myocardial reperfusion injury [20]. This study was based on the 
hypothesis that thrombolysis in the absence of plasmin generation could result in improved myocardial 
salvage. The authors examined the thrombolytic effect of recombinant t-PA (rt-PA) (0.022 mg/kg, 
10% delivered as a loading dose and 90% infused over 60 minutes by intracoronary administration) vs. 
alfimeprase  (0.5  mg/kg  over  1  minute  by  intracoronary  administration)  in  a  canine  model  of 
electrolytic injury to the left circumflex coronary artery (LCX). Both agents induced thrombolysis, 
with alfimeprase being more rapid with onset of reperfusion in 1.5 ±  0.6 vs. 10.1 ±  2.1 minutes for rt-
PA. In the absence of adjuvant anti-platelet therapy, however, time to reocclusion was much shorter 
with alfimeprase (3.2 ±  0.5 minutes vs. 77.5 ±  31.9 minutes for rt-PA). In a separate group of animals, 
the  presence  of  a  glycoprotein  IIb/IIIa  platelet  receptor  antagonist  dramatically  prolonged  time  to 
reocclusion for both agents: alfimeprase was 163.3 ±  27.4 min and rt-PA was 142.8 ±  34.5 min. The 
effect on myocardial infarct size was examined after dogs were exposed to 60 min of LCX occlusion 
followed by intracoronary agent delivery, and after 4 h of reperfusion, infarct size was measured. The 
myocardial  infarct  size  after  alfimeprase  was  19.9%  ±   3.6%  of  risk  region  and  
32.2% ±  4.0% after rt-PA, vs. 18.5% ±  3.3% for saline control [20]. Thus, local administration of 
alfimeprase produced a significant advantage both in the shorter time to onset of reperfusion as well as 
smaller size of myocardial infarct as compared to rt-PA. The generation of plasmin by rt-PA could be 
associated with secondary proteolytic effects that lead to larger infarct size. The alfimeprase results 
were obtained with no evidence of altered hemostasis or bleeding at remote sites since 2M limits 
alfimeprase lytic action to the site of application. Others have suggested that plasminogen activators 
activate  enzyme  systems  with  pro-inflammatory  effects,  which  contribute  to  the  pathogenesis  of 
ischemia-reperfusion  injury.  Thus,  rt-PA  appears  to  be  associated  with  greater  risk  of  myocardial 
reperfusion injury than alfimeprase [20]. 
An  acute  ischemia-reperfusion  stroke  model  in  rats  was  performed  to  evaluate  the  activity  of 
alfimeprase vs. rt-PA following reperfusion of the middle cerebral artery after 5-hour occlusion [21]. The 
blinded study compared 10 minute infusion immediately after reperfusion using alfimeprase at 0.03, 
0.1  and  0.3  mg/kg  vs.  rt-PA  at  1  mg/kg.  Analysis  of  brain  sections  of  treated  animals  with  an 
alfimeprase dose of 0.03 mg/kg revealed that the hemorrhagic transformation frequency, neurological 
deficit and mortality rate were much lower than for rt-PA; at higher doses of alfimeprase there were no 
differences  vs.  rt-PA.  There  were  no  significant  differences  in  infarction  and  blood-brain  barrier Toxins 2010, 2                                    
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permeability when comparing control, 0.1 mg/kg alfimeprase and 1 mg/kg rt-PA. This study indicated 
a similar safety profile of alfimeprase and rt-PA [21].  
In conclusion, the in vivo studies revealed that alfimeprase could be used to successfully lyse clots in 
a  number  of  animal  models  of  arterial  thrombosis  (Table  2).  In  all  models  alfimeprase  was 
administered  locally  to  avoid  2M  inhibition  and  the  enzyme  was  shown  to  act  across  species. 
Alfimeprase did not increase hemorrhage in a rat ischemic stroke model vs. recombinant t-PA (rt-PA), 
nor  lead  to  other  neurological  problems  [21].  Thrombi  were  effectively  and  quickly  cleared,  and 
alfimeprase  did  not  promote  rethrombosis.  Since  alfimeprase  is  rapidly  inactivated  in  the  general 
circulation by 2M, the enzyme appears to offer promise as a safe, effective and specific agent for 
thrombolysis when administered locally at the site of the thrombus [22]. A number of US patents have 
been issued for alfimeprase [23]. 
6. Clinical Trials 
The in vitro and animal model studies on fibrolase and alfimeprase were aimed to advance the 
protein toward clinical trials. Nuvelo (at that time known as Hyseq; San Carlos, CA), obtained in 2002 
the rights to alfimeprase from Amgen and initiated clinical trials. Twenty years had elapsed from the 
time the protein was first reported by the Markland laboratory [3] and the start of clinical trials (Table 1). 
A Phase I clinical trial was designed to evaluate the safety profile, pharmacokinetics, and thrombolytic 
activity  of  alfimeprase  in  patients  with  chronic  peripheral  arterial  occlusion  (PAO).  PAO  or  “leg 
attack” is caused by a blood clot that causes blockage of arterial blood flow to a lower limb. This 
underlying peripheral arterial disease, if untreated can lead to nerve and muscle damage, gangrene and 
in severe cases amputation and death. Treatment involves rapid restoration of arterial patency and 
blood flow, as well as limb preservation. PAO affects more than 100,000 people per year in the United 
States and an equal number in Europe. 
The  Phase  I  trial  was  a  multicenter,  open-label,  single-dose,  dose-escalation  study,  involving  
20 patients with worsening symptoms of lower extremity ischemia who were treated with alfimeprase 
in five escalating dose cohorts (0.025, 0.05, 0.1, 0.3, and 0.5 mg/kg) [18]. The United States FDA 
granted orphan drug status to alfimeprase for the Nuvelo clinical trial for PAO. Orphan drug status was 
created by the FDA for agents used to treat diseases that occur in less than 200,000 cases or where 
there is no hope of recovering the development costs for the Company, so there is little financial 
incentive  to  develop  these  drugs.  Granting  orphan  drug  status  provides  the  manufacturer  specific 
financial incentives to provide the drug. A pulsed infusion delivery modality for alfimeprase was used 
either  intraarterial  or  sometimes  intrathrombus.  The  primary  endpoint  was  safety  as  assessed  by 
adverse event rates. Additional safety assessments included 2M, and anti-alfimeprase antibodies for 
as long as 3 months after treatment. Pharmacokinetic parameters were evaluated with use of an assay 
that measures free and 2M-bound (total) alfimeprase. The study was conducted in 7 US hospitals by 
Nuvelo and was completed in March of 2003. There were no deaths and none of the patients experienced 
adverse hemorrhagic events. Further, the mean plasminogen and fibrinogen concentrations were not 
substantially altered by treatment. There were three transient, treatment-related adverse events; all were 
mild and in the same patient. The half-life for alfimeprase ranges from 11 to 54 minutes (median,  
25 min) in patients with PAO. Serum 2M decreased transiently in a dose-dependent manner after Toxins 2010, 2                                    
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treatment, but returned to normal ~14 days after treatment. Alfimeprase doses were selected to be 
within  the  alfimeprase-binding  capacity  of  2M,  which  was  1.71  mg/kg.  The  Phase  I  trial 
demonstrated that alfimeprase in doses as high as 0.5 mg/kg (within the binding capacity of 2M) was 
generally safe in patients with chronic PAO. There were no bleeding complications and no systemic 
thrombolysis was noted. Further, the stable fibrinogen concentrations suggest that alfimeprase action is 
limited  to  the  target  thrombus.  There  were  no  instances  of  anaphylaxis  and  no  anti-alfimeprase 
antibodies three months after alfimeprase administration. None of the serious adverse events were 
attributed  to  alfimeprase.  Thus,  this  Phase  I  clinical  trial  demonstrated  that  alfimeprase  holds  the 
potential to achieve dissolution of PAO with minimal risk of hemorrhage [24,25]. 
NAPA-1 (Novel Arterial Perfusion with Alfimeprase), which was a Phase II trial, commenced in 
July 2004, and was a multinational, open label, dose escalation trial in 113 acute PAO patients. The 
primary  objective  was  safety,  and  a  secondary  objective  was  efficacy.  Alfimeprase  (0.1,  0.3  or  
0.6 mg/kg, 2/3 then 1/3 of dose administered 2 h apart via side-hole catheter placed into the thrombus) 
was administered in 1 mL pulses at 1 pulse/min. Patients were enrolled within 14 days of symptoms 
and all patients were over 18 years old. Alfimeprase lysed thrombi at a rate of up to 76%, restored 
arterial flow up to 60% within 4 h of dosing and 52%–69% of patients avoided surgical intervention. 
There were no intracerebral hemorrhages or deaths, and only one major and three minor bleeds as far 
as Adverse Events (AE) that could possibly be attributed to alfimeprase (patients received aspirin and 
heparin). There was transient hypotension at high dose but this could be easily managed and 2M 
dropped 40%–60% but recovered by day 14 [25]. 
The Phase 3 Trials, NAPA-2 starting in April 2005, and NAPA-3 starting in April 2006, were 
overlapping,  randomized,  multinational  trials,  in  which  0.3  mg/kg  alfimeprase  was  compared  to 
placebo. The intent was to enroll ~600 patients worldwide with symptom onset within 14 days. The 
primary endpoint was avoidance of open vascular surgery within 30 days of alfimeprase treatment; 
secondary endpoints were rate of arterial flow restoration at 4 h after drug administration and rate of 
improvement in ankle brachial index at 30 days (Table 3). The AE and severe AE (SAE) were major 
bleeding,  intra-cranial  hemorrhage,  peripheral  embolic  events,  all  cause  mortality  and 
pharmacoeconomics such as length of hospital stay. NAPA-2, was a partial double-blind study with 
4:3:1  randomization  between  intrathrombus  alfimeprase,  intrathrombus  placebo,  and  perithrombus 
placebo. Alfimeprase was administered 2/3 of total dose given initially and then 1/3 dose given 2 h 
later.  By  comparison,  NAPA-3  was  a  double-blind  study  with  1:1  randomization  between  
intra-thrombus alfimeprase and intrathrombus placebo, using the same drug administration schedule, 
2/3 of total dose and then 1/3 dose given 2 h later. In January 2006 alfimeprase was granted fast track 
designation  for  the  NAPA-3  trial  for  PAO.  Fast  track  designation  facilitates  development  and 
expedited review of new drugs that demonstrate the potential to address an unmet medical need and 
are intended for treatment of serious or life-threatening conditions. During the NAPA-2 and -3 studies 
Dr. Fred Weaver, a vascular surgeon at USC and leader of the alfimeprase clinical trial at the Keck 
School of Medicine site at USC, and his colleagues, noticed that there was a correlation between the 
length of the thrombus and the success of lysis by alfimeprase: for short occlusion lengths (<10 cm or 
from  10  cm  to  <20  cm)  the  difference  in  flow  restoration  at  4  hours  between  alfimeprase  and 
intrathrombus placebo was virtually nonexistent, whereas for an occlusion length of 40 cm the 4 hour 
flow restoration rate was 45.5% for alfimeprase and only 16.7% for placebo. This correlation also held Toxins 2010, 2                                    
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when there was no early decline in circulating 2M level, where the 4-hour flow restoration rate for 
alfimeprase  was  70%,  whereas  for  placebo  it  was  37%.  These  results  suggested  to  Weaver  and 
colleagues that when alfimeprase is trapped in longer thrombi and is not released into the general 
circulation, where it interacts with 2M causing rapid depletion of 2M, the enzyme is degrading the 
thrombus leading to more rapid flow restoration in the longer thrombi [26]. These findings suggested 
that there may have been some flaws in the side hole catheter delivery mechanism and that alternative 
delivery methodologies with improved residence in the clot should be explored. 
Table 3. NAPA-2 and NAPA-3 trials: primary and secondary endpoint results 
†. 
  NAPA-2  NAPA-3 (interim) 
ALF*  
(n = 149) 
IT Placebo 
(n = 113) 
PT Placebo 
(n = 38) 
ALF  
(n = 51) 
IT Placebo 
(n = 51) 
Rate of 30-day open 
vascular surgery avoidance 
34.9%  37.2%  18.4%  29.4%  17.6% 
Rate of restoration of 
arterial flow at four hours  46.3%  37.2%  15.8%  35.3%  23.5% 
Rate of 30-day ABI** 
improvement  
24.8%  23.0%  7.0%  11.8%  7.8% 
 
† Data adapted from Han, SM, Weaver, FA, et al. [26]; *ALF = alfimeprase, ABI = ankle-brachial 
index; ** The Ankle-Brachial Index is the ratio of blood pressure in the lower legs to the blood 
pressure in the arms. Lower blood pressure in the leg is an indication of blocked arteries (PAO). 
 
In  summary,  the  Phase  III  NAPA  trials  did  not  meet  the  primary  endpoint  and  showed  no 
significant difference between the intrathrombus alfimeprase and intrathrombus placebo groups [26]. 
The greater efficacy observed in longer clots and with a smaller drop in 2M levels, suggested that 
improved drug retention in the clot might improve lysis. AE profile in alfimeprase treated patients 
differed between NAPA-2 and NAPA-3 with the NAPA-3 trials being more favorable for alfimeprase. 
In  both  trials  the  majority  of  hypotensive  episodes  occurred  within  15  minutes  of  alfimeprase 
administration  without  apparent  clinical  sequelae.  The  risk  of  hypotension  increases  with  use  of  
anti-hypertensives,  particularly  renin-angiotensin  antagonists.  Hypotension  may  be  related  to  local 
bradykinin generation induced by alfimeprase as discussed above (see Figure 1). As far as hemorrhage, 
in NAPA-2 the majority were due to catheter site bleeding (23.0% intrathrombus alfimeprase vs. 10.8% 
intrathrombus placebo) and surgical bleeding (6.1% intrathrombus alfimeprase vs. 1.7% intrathrombus 
placebo).  Major  hemorrhage  was  higher  with  intrathrombus  alfimeprase  (5.4%)  vs.  intrathrombus 
placebo (0.9%). In NAPA-3 the catheter site bleeding was confirmed, but no surgical bleeding or major 
hemorrhage risk was observed. Finally, interim analysis of NAPA-3 showed favorable efficacy trends, 
but the sponsor decided the delivery method was not optimal and terminated the study. A further 
evaluation is warranted to improve and optimize the delivery system for alfimeprase to maximize 
retention of drug in the thrombus and increase lytic activity in PAO. 
The second clinical application of alfimeprase was central venous access device (CVAD) occlusion. 
This is a big market as about five million catheters are positioned annually in the United States to 
deliver  chemotherapy,  nutrients,  antibiotics  and  blood  products,  and  up  to  25%  of  them  become Toxins 2010, 2                                    
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occluded. Because of the direct fibrin degradation activity of alfimeprase, it was hypothesized that in 
patients  with  an  occluded  CVAD  there  would  be  rapid  clot  dissolution  following  alfimeprase 
treatment. A Phase II randomized, double-blind, active-control, multicenter, dose-ranging trial was 
initiated with patients enrolled between May 2003 and August 2004. Safety and efficacy of one or two 
instillations of 3 intraluminal doses of alfimeprase (0.3, 1.0 and 3.0 mg) or alteplase 2.0 mg were 
compared (alteplase is a version of recombinant t-PA developed by Genentech) [27,28]. The ability of 
alfimeprase to re-establish patency in 55 adult patients with occluded CVADs was investigated in this 
Phase II trial. Alfimeprase was shown to restore CVAD function in up to 60% of treated patients in 
less than 30 minutes, with the majority of these successes occurring in 15 minutes or less with 3 mg of 
alfimeprase.  This  rapid  activity  was  associated  with  an  acceptable  and  favorable  safety  profile. 
Alfimeprase  treatment  was  well  tolerated,  with  no  intracranial  hemorrhage  or  any  other  major 
hemorrhagic or embolic events reported for any of the patients. There were no adverse events that 
suggested a safety concern. In conclusion, this Phase II trial demonstrated that all three alfimeprase 
doses were more successful than alteplase at 5, 15 and 30 min during the first treatment. Alfimeprase 
at the 3.0 mg dose resulted in 40%, 50%, and 60% patency restoration rates at 5, 15, and 30 min, 
compared with 0%, 0%, and 23% for alteplase. Alfimeprase at 3.0 mg produced the highest patency 
rate at 120 min after the first (60%) and second (80%) doses (Table 4), and no major hemorrhagic or 
embolic events were reported [29,30].  
Table 4. Clinical Potency of Alfimeprase vs. Alteplase in Patients with CVAD Occlusion 
† 
Cumulative Catheter Clearance Rate (%). 
First dose 
ALF* 0.3 mg 
(n = 16) 
ALF 1 mg 
(n = 16) 
ALF 3 mg 
(n = 10) 
Alteplase 2 mg 
(n = 13) 
5 min  13  13  40  0 
15 min  13  44  50  0 
30 min  25  44  60  23 
120 min  38  56  60  46 
Second dose         
5 min  38  56  60  54 
15 min  38  56  60  62 
30 min  38  56  60  62 
120 min  44  56  80  62 
† Data adapted from [29,30]; *ALF = alfimeprase. 
 
Following these favorable results, a Phase III trial was then initiated called SONOMA-2 (Speedy 
Opening of Non-functional and Occluded catheters with Mini-dose Alfimeprase). The trial was initiated 
in September 2006 and was a double blind trial comparing efficacy and safety of 3 mg of alfimeprase vs. 
placebo and was to include 303 patients with CVAD occlusion. The primary endpoint was the restoration 
of function to occluded catheters in 15 minutes. Unfortunately, it was announced in December 2006 that 
the trial did not meet the end point of restoration of function of occluded central venous catheters in  
15 min. Alfimeprase restored catheter function in 15 min but with a p-value of 0.022, it did not meet the 
more  stringent  p-value  of  <0.00125  required  of  this  trial.  Also,  the  trial  did  not  meet  established 
secondary  endpoints  and  enrollment  in  the  new  SONOMA-3  trial  was  temporarily  suspended  in Toxins 2010, 2                                    
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December 2006. However, SONOMA-3 was reopened in August 2007 as an open-label, single-arm trial of 
alfimeprase alone using a 10 mg dose at 5 mg/mL in up to 100 patients. The primary endpoint was safety; 
efficacy was also evaluated. Alfimeprase restored catheter function in ~50% of patients in 15 min and 
~60% at 1 h, better than in the SOMOMA-2 trial, but not good enough. By comparison CathfloTM 
Activase® (alteplase or rt-PA), cleared ~80% of occluded catheters in patients by 2–4 h. Alfimeprase 
was to restore catheter function with similar efficacy to CathfloTM Activase®, but in a shorter time. In 
combination with poor results in NAPA-3, Nuvello decided to abandon the development of alfimeprase 
in March 2008 (http://www.bizjournals.com/sanjose/stories/2008/03/17/daily14.html?t=printable).  
Prior to dropping the alfimeprase project,  Nuvello had initiated a Phase II clinical trial in acute 
ischemic stroke (http:www.fiercebiotech.com/node/13455/print). Fast track designation for alfimeprase 
was granted for this proof of concept study. Stroke is the third leading cause of death in the United 
States, with about 700,000 cases per year, and a significant cause of long-term disability. Stroke is 
caused when a blood vessel that is carrying nutrients and oxygen to the brain becomes blocked by a 
blood clot (ischemic stroke) or ruptures due to some causative factor (hemorrhagic stroke). There is an 
urgent need for agents that can remove the thrombus in ischemic stroke in patients who present at 
greater  than  3  hours  after  the  event.  The  acute  ischemic  stroke  trial  with  alfimeprase  was  called 
CARNEROS-1  (Catheter  directed  Alfimeprase  for  Restoration  of  NEurologic  function  and  Rapid 
Opening of arteries in Stroke). The study was initiated in June 2007 and the first patient was treated in 
December 2007. The trial was a multi-center, open label, dose escalation study starting with doses of  
1, 5 and 10 mg of alfimeprase in ~100 patients with acute ischemic stroke. Patients were treated within 
3–9 h of onset of stroke. The endpoints to be observed were safety and efficacy in stroke patients 
treated  with  intra-arterial,  catheter  directed  bolus  alfimeprase.  The  primary  efficacy  endpoint  was 
recanalization of main occlusive lesion within 120 min of alfimeprase treatment; safety was assessed 
by a lack of symptomatic intracerebral hemorrhage within 24 h of drug administration. Due to lack of 
enrollment in this trial as well as the failed Phase III trials in CVAD and PAO, Nuvelo decided to 
terminate  this  study.  Thus,  in  March  2008,  Nuvelo  discontinued  the  clinical  development  of 
alfimeprase and the program was shut down [23]. 
7. Conclusions 
The results of the Phase I trials to evaluate the safety profile, pharmacokinetics, and thrombolytic 
activity of escalating doses of alfimeprase in patients with chronic peripheral arterial occlusion (PAO) 
were very promising and there was limited toxicity [25]. In the Phase II trials (safety and efficacy) 
there were a low number of major hemorrhagic events in both PAO [18] and CVAD occlusion [18,30] 
trials. Importantly, there was a lack of intracerebral hemorrhage in all trials. The use of alfimeprase 
resulted in rapid restoration of arterial patency in <4 h in most PAO patients. In the CVAD occlusion 
trial, alfimeprase restored patency in <30 min with no evidence of hypotension. In both PAO and 
CVAD occlusion trials there was no evidence of anti-alfimeprase antibodies. These trials indicated that 
alfimeprase has the potential to be a potent direct-acting fibrinolytic agent with an excellent safety 
profile.  As  observed  for  fibrolase,  alfimeprase  is  rapidly  inactivated  by  2M  after  forming  a  
1:1 complex; a covalent bond forms between 2M and alfimeprase [22,31]. Inhibition of alfimeprase 
by 2M in the circulation limits fibrinolytic action to the site of the clot. Extensive studies with human Toxins 2010, 2                                    
 
806 
blood serum from several hundred volunteers were used to accurately estimate the level of 2M in 
human blood; this established an upper limit for alfimeprase use in humans. This analysis revealed that 
the alfimeprase binding capacity is directly proportional to the measured 2M content. When these 
data were used to calculate a theoretical dose of alfimeprase on a “mg/kg” basis, the mean estimate for 
the population was 1.7 mg/kg [8]. Although some individuals were theoretically capable of tolerating 
nearly 4 mg/kg of alfimeprase, some in the population might tolerate dosages of only 0.6 mg/kg. In 
view of these results, clinical dosages in the first human trial of alfimeprase did not exceed 0.5 mg/kg.  
Despite these findings, transient bouts of hypotension were experienced at the highest doses in the 
PAO trial [18,22]. These cases spontaneously resolved or could be easily managed by supportive care 
including bradykinin receptor antagonist or nitric oxide synthetase inhibitor [24]. Bolus delivery of 
alfimeprase  through  an  intrathrombus  side-hole  catheter  in  the  PAO  trial  represents  a  mechanical 
manipulation, which creates channels resulting in clot disruption and run-off of alfimeprase; it is then 
inactivated in the circulation by 2M. The inability to maintain alfimeprase in the thrombus long 
enough to lyse the full-length of the clot is probably related to the delivery modality. It appears that 
there was also a problem with the dose and dosing schedule in addition to the delivery problem. The 
use of a catheter that sprays alfimeprase into the thrombus requires that the catheter penetrate into the 
clot and deliver the lytic agent into the depths of the thrombus mass. The danger is that the disrupted 
clot could dislodge and move distally, creating an embolus most likely due to the mechanical effect of 
the pulsatile delivery. 
Finally, the failures to meet endpoints in the Phase III CVAD occlusion trial [23] and the Phase III 
PAO trial [26] were problematic as was poor enrollment in the Phase II CARNEROS-1 (stroke) trial 
(http://clinicaltrials.gov/ct2/show/NCT00499902).  Thus,  in  March  2008  Nuvelo  discontinued 
development of alfimeprase (http://www.fiercebiotech.com/node/20663/print). Is there anything that 
can be done to salvage this technology in the future? Among the areas that might be considered: the 
use  of adjuvant  antiplatelet  therapy;  adjusting the dosage regimen; drug  interactions such  as with 
antiplatelet agents, which may be synergistic in nature; the use of a placebo control for the PAO trials 
based on the report by Han et al. [26]; the use of magnitude of surgical intervention as opposed to 
avoidance of open vascular surgery as end point for the PAO trial; and finally, further evaluation is 
warranted to optimize the mode of delivery and dose for alfimeprase. This final issue is critical to the 
success of alfimeprase and the ability to maximize retention of the drug at the thrombus site and 
increase lytic activity.  
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